Recent Advances in Radiofrequency Ablation for the Management of Hepatocellular Carcinoma


avatar Takashi Himoto 1 , * , avatar Kazutaka Kurokohchi 2 , avatar Seishiro Watanabe 3 , avatar Tsutomu Masaki 2

Department of Integrated Medicine, [email protected], Japan
Department of Gastroenterology and Neurology, School of Medicine, Kagawa University, Japan
Department of Internal Medicine, Kagawa Prefectural Central Hospital, Japan

how to cite: Himoto T, Kurokohchi K, Watanabe S, Masaki T. Recent Advances in Radiofrequency Ablation for the Management of Hepatocellular Carcinoma. Hepat Mon. 2012;12(10):5945. doi: 10.5812/hepatmon.5945.



Hepatocellular carcinoma (HCC) is one of the most common malignant diseases in the world. Because less than 20% of patients with HCC are resectable, various types of non-surgical treatment have been developed.

Evidence Acquisition:

At present, radiofrequency ablation (RFA) is accepted as the standard local treatment for patients with HCC because of its superior local control and overall survival compared to other local treatments.


New devices for RFA and combination treatments of RFA with other procedures have been developed to improve anti-tumoral effects.


This review mainly focuses on the status of RFA in the management of HCC and recent advances in RFA treatment technology.

Full Text

Full text is available in PDF

© 2012, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.